June 25 (Reuters) - AstraZeneca's (AZN.L), opens new tab blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a ...

(Reuters) - AstraZeneca Plc's immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday. The study ...

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An AstraZeneca logo is pictured in Brussels (Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in ...